ZAVICEFTA®: Decisive action against difficult-to-treat infections due to aerobic Gram-negative bacteria

Read More

ZINFORO®: A smart choice for patients when there is no time to wait

Read More

ZAVICEFTA®: Decisive action against difficult-to-treat infections due to aerobic Gram-negative bacteria

ZAVICEFTA® is indicated for the treatment of:*1

  • HAP, including VAP
  • cUTI, including pyelonephritis
  • cIAI
  • Infections due to aerobic Gram-negative organisms in adult patients with limited treatment options

A novel combination of ceftazidime and avibactam, providing expanded aerobic Gram-negative coverage1

Find out more on Pfizer Pro
  • Proven efficacy in HAP/VAP, cUTI and cIAI2–5

    • Established in four large Phase III clinical trials2–5
    • The new REPROVE trial confirmed comparable efficacy to meropenem in the treatment of HAP/VAP5
  • Bactericidal activity against aerobic Gram-negative pathogens, including resistant strains1–6

    • Pseudomonas aeruginosa (including ceftazidime-resistant strains)2,7
    • ESBL-producing Enterobacteriaceae8–10
    • Carbapenem-resistant Enterobacteriaceae8,9,11
    • ZAVICEFTA® inhibits class A, C and some D β-lactamases, including ESBLs, KPC, OXA-48 and AmpC✝1,6
  • Safety and tolerability profile consistent with other cephalosporins2

    • In Phase III clinical trials, the adverse event profile of ZAVICEFTA® was similar to that seen with either best available therapy, doripenem or meropenem2–5
    • In vitro, ZAVICEFTA® demonstrated neither synergy nor antagonism with the following drugs: metronidazole, tobramycin, levofloxacin, vancomycin, linezolid, colistin and tigecycline1

ZINFORO®

(ceftaroline fosamil) is now available from Pfizer

ZINFORO®: Indicated for the treatment of the following infections in adults and children from the age of 2 months*12

CAP

(Community-acquired pneumonia)

cSSTI

(Complicated skin and soft tissue infections)

ZINFORO® is a fifth-generation cephalosporin with an extended spectrum of activity relative to third-generation compounds13

Find out more on Pfizer Pro
  • Proven efficacy in CAP and cSSTI14–19

    • Established in six large Phase III trials14–17
    • Substantiated by real-world evidence18,19
  • Evidence of early clinical response20,21

    ZINFORO® showed evidence of early clinical response rates including in high-risk patients with comorbidities:

    • At Day 4 in CAP20
    • Day 3 in cSSTI21
  • Gram-negative and Gram-positive coverage‡12,14,16

    Including key pathogens in CAP14 and cSSTI16

  • Successful outcomes in real-world patients18,19,22

    High clinical success rates in:

    • CAP patients, including the elderly and those with multiple comorbidities19
    • cSSTI patients, including those with comorbidities and those who are obese18,22
  • Safety and tolerability profile consistent with other cephalosporins14,16

    • Suitable for use in patients with comorbidities14,16,18,19
    • Safety profile in the paediatric population similar to that observed in adults§12